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References
Table 1. Survey Respondents
Table 3. Comfort, Knowledge, and Beliefs
• Institutional Review Board (IRB)-approved 
• Comparison of pre and post survey responses following 
an academic detailing intervention (two 45 minute 
required sessions)
• Academic detailing learning objectives:
• Review the use of buprenorphine for OUD
• Describe medications for withdrawal symptom 
management
• Identify resources to aid in MAT
• Apply principles of treatment with buprenorphine 
to patient cases
• Inclusion criteria: CPSs at PMG primary care clinics in 
Oregon and SW Washington
• Exclusion criteria: none
• Primary outcome:
• CPS comfort with and knowledge of 
buprenorphine in MAT for OUD
• Secondary outcome: 
• Number of patients with a CPS involved in the 
care of their OUD
• The primary outcome was analyzed using a Wilcoxon-
rank-sum test with a two sided p-value
Respondents
• 19 participants responded to the pre-survey and 20 
responded to the post survey
• 4/19 (21.05%) respondents to the pre-survey were 
currently active in MAT. Of these, 3 indicated they were 
involved in MAT for 1-5 patients annually, and 1 indicated 
they are involved with MAT for 20+ patients annually. 
Respondents’ demographics are included in Table 1
• There was no change in the number of CPSs involved in 
MAT in the time between the two surveys
Barriers
• The three most common barriers identified were a lack of 
time (23.08%), lack of X-waivered providers in clinic 
(23.08%), and lack of knowledge (21.15%) (Figure 1)
• The factor most commonly rated as the #1 barrier was a 
lack of X-waivered providers in clinic (38.89%)
Comfort, Knowledge, and Beliefs
• Pre and post survey results are listed in Table 3.
• All responses were statistically significantly improved 
following the academic detailing intervention, with the 
exception of two questions regarding medication use for 
withdrawal symptoms and the role of a CPS in MAT for 
OUD (p>0.05)
Study Limitations
• Data collected through the use of surveys is susceptible to 
response bias
• Academic detailing interventions were specific to 
respondent’s identified barriers and may not be applicable 
to every primary care practice site
• CPS involvement in MAT is dependent on provider’s ability 
to prescribe buprenorphine
• Respondents to the pre-survey and post-survey were 
unable to be matched for analysis
1. Centers for Disease Control and Prevention. Opioid Overdose. Accessed October 29, 2019.
2. US Department of Health and Human Services. HHS acting secretary declares public health emergency to 
address national opioid crisis. http://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-
public-health-emergency-address-national-opioid-crisis.html. Accessed October 29, 2019.
3. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet 
formulation of buprenorphine and naloxone. N Engl J Med. 2003 Sep 4;349(10):949-58.
4. Larochelle MR, Bernson D, Land T, et al. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose 
and Association With Mortality: A Cohort Study. Ann Intern Med. 2018;169(3):137-145.
5. Giberson S, Yoder S, Lee MP. Improving Patient and Health System Outcomes through Advanced Pharmacy 
Practice. A Report to the U.S. Surgeon General. Rockville, MD: Office of the Chief Pharmacist, US Public 
Health Service; 2011.
To identify and address common barriers to Clinical 
Pharmacy Specialist (CPS) involvement in medication 
assisted treatment (MAT) for opioid use disorder (OUD) 
through academic detailing interventions to improve CPS 
comfort level with MAT for OUD, and increase the number of 
patients with a CPS involved in the treatment of their OUD.
• This study was conducted to identify and address barriers 
to determine if this increases CPS involvement in MAT
• Most CPSs within PMG are not currently involved in the 
use of buprenorphine in MAT for OUD, due to a 
combination of different barriers
• Academic detailing can significantly impact CPSs’ comfort 
with MAT for OUD, including:
• The use of buprenorphine in induction and 
maintenance
• Talking to providers about the role of a CPS in 
MAT for OUD
• Finding workflows and resources to assist in the 
use of buprenorphine for MAT
Background
• Opioid prescribing and overdose deaths began 
increasing in the 1990s, and continued for decades, 
reaching a 6-fold increase between 1999 to 2017 1,2
• MAT is a method of treating substance use disorders 
using a combination of counseling, behavioral therapy, 
and FDA-approved medications1
• The use of buprenorphine in MAT for the treatment of 
OUD has been shown to reduce the use of opiates, 
cravings for opiates, and risk of all-cause and opioid-
related mortality, but remains under-utilized in primary 
care settings3,4
• CPSs have been shown to improve health outcomes, 
increase cost-effectiveness, and improve the quality of 
health care through collaborative, evidence based 
patient care services for chronic disease states5
• Despite the potential to improve outcomes through 
collaborate practice, CPS involvement in the treatment 
of OUD remains limited5
• The current involvement and perceived barriers among 
the 26 CPS within a large medical group are unknown. 
Identifying and addressing these barriers through 
academic detailing will encourage their involvement in 
MAT for OUD
Methodology
• Identify and describe the most common barriers to CPS 
involvement in MAT for OUD
• Assess the impact of academic detailing on clinical 
pharmacy specialists’ (CPS) comfort level with being 
involved in the care of patients undergoing MAT for OUD
• Assess the hypothesis that academic detailing will lead to 
an increase in the number of patients with a CPS involved 
in the treatment of their OUD
Primary Outcome Results
Health & Services
Respondents
Pre-survey, No. 19
Post-survey, No. 20
Years in Practice
0-2 years, No. (%) 7 (36.84)
3-5 years, No. (%) 7 (36.84)
6-10 years, No. (%) 3 (15.79)
10+ years, No. (%) 2 (10.53)
Table 2. Prescribing Habits
Survey Question SA A N D SD P value
I feel comfortable explaining 
the role of a Clinical 
Pharmacist in MAT to my 
providers.
Pre 5.26% 26.32% 31.58% 31.58% 5.26%
0.004
Post 10% 70% 20% 0% 0%
I feel comfortable managing 
patients on buprenorphine 
for MAT.
Pre 5.26% 10.53% 31.58% 36.84% 15.79%
0.012
Post 5% 40% 45% 5% 5%
I feel confident in my ability 
to conduct a buprenorphine 
induction.
Pre 5.26% 10.53% 15.79% 42.11% 26.32%
0.012
Post 0% 35% 40% 25% 0%
I feel confident in my ability 
to treat patients with 
buprenorphine during the 
maintenance phase.
Pre 5.26% 10.53% 21.05% 52.63% 10.53%
0.001
Post 15% 45% 35% 5% 0%
I feel confident in my 
knowledge of the 
medications used to treat
withdrawal symptoms .
Pre 5.26% 42.11% 21.05% 31.58% 0%
0.250
Post 5% 55% 35% 5% 0%
I know where to find 
workflows /resources to 
assist in treating patients on 
MAT.
Pre 15.79% 47.37% 21.05% 15.79% 0%
0.034
Post 30% 70% 0% 0% 0%
I understand the role of a 
Clinical Pharmacy Specialist 
in MAT in primary care.
Pre 5.26% 52.63% 5.26% 36.84% 0%
0.051
Post 10% 80% 10% 0% 0%
My level of knowledge 
about the use of 
medications for MAT is 
sufficient.
Pre 5.26% 10.53% 26.32% 47.37% 10.53%
0.011
Post 0% 45% 40% 15% 0%
SA: Strongly Agree; A: Agree; N: Neutral; D: Disagree; SD: Strongly Disagree
23.08%
23.08%
21.15%
15.38%
7.69%
7.69% 1.92% Lack of time
Lack of X-waivered providers in clinic
Lack of knowledge regarding MAT
Other
Challenging patient population
Low volume of patients needing MAT
Provider unwillingness to involve clinical pharmacy
Figure 1. Barriers
Involvement in MAT
Currently involved, No. (%) 4 (21.05)
Inductions only, No. (%) 2 (10.53)
Inductions and maintenance, No. 
(%) 2 (10.53)
Clinics with ≥1 X-waivered 
provider, No. (%) 22 (62.86)
PMG buprenorphine
prescriptions, No. 1,038
X-waiver: DATA2000 waiver
Next Steps
CPS involvement in MAT will be re-assessed through the use 
of a survey or electronic database tracking in June 2020, and 
compared to involvement at the time of the pre-survey 
before the academic detailing intervention.
